TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28029540
Drug: One MenC‐TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: One MenC‐TT dose
Study: 28029540
Drug: Two MenC‐CRM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two MenC‐CRM vaccine doses
Study: 24929023
Drug: H2-saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-saline infusion (1 ppm H2-dissolved saline)
Study: 24929023
Drug: Placebo-saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-saline infusion
Study: 22344504
Drug: Enhanced eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Study: 22344504
Drug: Standard eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Study: 19546122
Drug: Silicone bulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone bulking agent injection
Study: 17587724
Drug: Azosemide (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azosemide (long-acting diuretic)
Study: 11305519
Drug: Glibenclamide (5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5-mg tablet) plus glucose (10% infusion at 62.5 ml/h for 12 h)
Study: 9356038
Drug: Combined infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined infusion of insulin and norepinephrine (NE)
Study: 1000195
Drug: Intravenous dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextran 70 and pneumatic leggings
Study: 26927446
Drug: CAP/BEV/VIN (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP/BEV/VIN (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w + vinorelbine at 25 mg/m² on days 1 + 8, q3w)
Study: 26927446
Drug: CAP/BEV (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP/BEV (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w)
Study: 19602719
Drug: Sitagliptin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 800 mg
Study: 17251808
Drug: 0.32% hypromellose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32% hypromellose solution
Study: 14734438
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (combination regimens)
Study: 12076220
Drug: NPPV by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPPV by face mask plus standard medical therapy (n = 39)
Study: 12076220
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy alone (n = 42)
Study: 9872357
Drug: High CDT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CDT group (CDT >20 U/l on admission)
Study: 9872357
Drug: Low CDT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low CDT group (CDT <= 20 U/l on admission)
Study: 24129613
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist co-treatment started on CD 2
Study: 24129613
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist co-treatment started on CD 6
Study: 21327806
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine 0.5 mg/kg
Study: 21327806
Drug: i.v. saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. saline 5 ml (control saline group)
Study: 12506278
Drug: Levodopa-carbidopa (1.86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa (1.86 mg/kg/day, 4:1 ratio) with occlusion therapy
Study: 12506278
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with occlusion therapy
Study: 7897117
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA) (100 mg over 3 h)
Study: 2766722
Drug: Norethindrone-1mg/mestranol-50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone-1mg/mestranol-50 micrograms formulations (1 + 50)
Study: 2766722
Drug: Norethindrone-1mg/ethinyl estradiol-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone-1mg/ethinyl estradiol-35 micrograms formulations (1 + 35)
Study: 783197
Drug: ouabain (0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: ouabain (0.015 mg/kg body weight)
Study: 783197
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ouabain administration)
Study: 21775883
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (burn wound debridement/topical antiseptic therapy) without ESWT
Study: 20329656
Drug: Formoterol HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol HFA formulation at 12 microg
Study: 20329656
Drug: Formoterol HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol HFA formulation at 24 microg
Study: 20329656
Drug: Reference formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formoterol HFA preparation
Study: 17426090
Drug: rhIGF-I/rhIGFBP-3 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-I/rhIGFBP-3 (1 mg/kg.d)
Study: 17426090
Drug: rhIGF-I/rhIGFBP-3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-I/rhIGFBP-3 (2 mg/kg.d)
Study: 17426090
Drug: rhIGF-I/rhIGFBP-3 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-I/rhIGFBP-3 (1 mg/kg.d) and (2 mg/kg.d)
Study: 17426090
Drug: rhIGF-I/rhIGFBP-3 (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-I/rhIGFBP-3 (highest dose groups)
Study: 11802044
Drug: 10‐mg single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg single dose of intramuscular injection of dexamethasone (n = 39)
Study: 11802044
Drug: 10‐mg single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg single dose of oral dexamethasone (n = 42)
Study: 7667171
Drug: Cyproheptadine HCl
Normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine HCl 4 mg 4 times/day
Study: 7667171
Drug: Cyproheptadine HCl
Normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine HCl 8 mg 4 times/day
Study: 2719760
Drug: Magnesium oxide,
Normalized name: Magnesium Oxide, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium oxide, 400 mg capsules, twice a day for 60 days
Study: 28851310
Drug: Warfarin (post-diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (post-diagnostic use)
Study: 28851310
Drug: Other types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other types of anticoagulants
Study: 28851310
Drug: Warfarin (pre-diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (pre-diagnostic use)
Study: 26316273
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g instant decaffeinated coffee with 100 mg caffeine
Study: 26316273
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g instant decaffeinated coffee with 100 mg caffeine
Study: 26316273
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g instant decaffeinated coffee with 100 mg caffeine
Study: 26316273
Drug: Control (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (400 ml water with 50 g glucose)
Study: 23147455
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of zonisamide (n = 76)
Study: 11054200
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diphenhydramine and 50 mg of ranitidine (active group)
Study: 11054200
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of diphenhydramine and saline solution (control group)
Study: 8764816
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 600 mg daily
Study: 3113295
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (180 microgram) administered 15 minutes prior to exercise
Study: 3113295
Drug: Cromolyn (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (20 mg) administered 15 minutes prior to exercise
Study: 3113295
Drug: Cromolyn (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (20 mg) administered 4 times/day for 2 or 4 weeks
Study: 24164537
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and L-asparaginase (experimental arm)
Study: 24164537
Drug: Standard-dose cytarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cytarabine, oral 6-mercaptopurine, and cyclophosphamide (standard arm)
Study: 23291141
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² plus cisplatin 25 mg/m² d1‐3 and 40 Gy of radiation therapy (Arm A)
Study: 23291141
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m² d1‐3 plus fluorouracil 600 mg/m² d1 ∼ 5 and 40 Gy of radiation therapy (Arm B)
Study: 18339420
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release oxybutynin 10 mg
Study: 18339420
Drug: Phenazopyridine 200
Normalized name: phenazopyridine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine 200 mg
Study: 15634033
Drug: Delavirdine 400mg
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine 400mg three times daily
Study: 12711838
Drug: NAC 600
Normalized name: Acetylcysteine 600 MG Oral Capsule [GNC NAC 600]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC 600 mg/day
Study: 12711838
Drug: NAC 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC 1,800 mg/day
Study: 12711838
Drug: NAC 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC 1,800 mg/day (after washout period)
Study: 12711838
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (control group A)
Study: 8527619
Drug: roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 150 mg in the early evening
Study: 8527619
Drug: roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 150 mg at bedtime
Study: 2312038
Drug: Ranitidine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine maintenance therapy
Study: 2312038
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment in patients with severe non-stenosing bulb deformity
Study: 2312038
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in patients with severe non-stenosing bulb deformity
Study: 2312038
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in patients with normal or mildly deformed bulb
Study: 2312038
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment in patients with normal duodenal bulb morphology
Study: 19263066
Drug: Pre-operative intravenous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intravenous dexamethasone (0.5 mg/kg) combined with glossopharyngeal nerve block (3 ml of 0.5% bupivacaine)
Study: 19263066
Drug: Pre-operative intravenous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intravenous dexamethasone (0.5 mg/kg)
Study: 19263066
Drug: Glossopharyngeal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glossopharyngeal nerve block (3 ml of 0.5% bupivacaine)
Study: 11772265
Drug: New antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antifungal agents (terbinafine, itraconazole, fluconazole)
Study: 7944842
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine (first or second intramuscular dose)
Study: 7944842
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine (revaccination)
Study: 3130253
Drug: Vigabatrin (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (1-3 g/day, stratified according to body weight)
Study: 17010732
Drug: Screening arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screening arm (prostate-specific antigen testing, digital rectal examination, transrectal ultrasonography, sextant biopsies)
Study: 12728489
Drug: Premedicated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedicated with oral midazolam 0.5 mg.kg‐1 (group A (+); n = 19)
Study: 31372099
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy and visceral manipulation
Study: 31372099
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy and placebo visceral manipulation
Study: 29967197
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose edoxaban regimen (60 mg QD)
Study: 29967197
Drug: Dose-reduced higher
Normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduced higher dose edoxaban regimen (30 mg QD)
Study: 29967197
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose edoxaban regimen (30 mg QD)
Study: 29967197
Drug: Dose-reduced lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduced lower dose edoxaban regimen (15 mg QD)
Study: 22219221
Drug: GSK598809 (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 (175 mg single oral dose)
Study: 22219221
Drug: GSK598809 (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 (175 mg single oral dose) + Alcohol infusion
Study: 15185803
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Mickey Mouse powered toothbrush
Study: 15185803
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B Rugrats 20)
Study: 12474069
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg Ca(2+))
Study: 2674028
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg xipamide + 30 mg triamterene (A)
Study: 2674028
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide + 50 mg triamterene (B)
Study: 11097613
Drug: 5‐fluorouracil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (50 mg/ml for 5 minutes)
Study: 11097613
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mitomycin C (0.4 mg/ml for 2 minutes)
Study: 1561975
Drug: Pacing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacing group (VVI or DDD pacemaker implant)
Study: 1561975
Drug: Nonpacing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpacing group (no therapy)
Study: 3929304
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg metergoline (MET)
Study: 3929304
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam (DZ)
Study: 29684147
Drug: Longer infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer infusions of Meropenem
Study: 26041481
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor (EGF) ointment
Study: 21516742
Drug: Intravenous alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alpha-lipoic acid (600 mg/day)
Study: 15630501
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) therapy during the first weeks of life
Study: 15630501
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) therapy
Study: 15630501
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Epo therapy)
Study: 2138172
Drug: 12% ammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% ammonium lactate lotion (Lac‐Hydrin) applied twice daily for 16 weeks
Study: 23551983
Drug: Intravenous propofol/midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propofol/midazolam
Study: 12774016
Drug: 500 ng/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ng/kg IL-12 subcutaneously twice weekly for 12 weeks
Study: 12774016
Drug: IL-12 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-12 therapy
Study: 11200372
Drug: Enterococcus faecium
Normalized name: Enterococcus faecium
DrugBank: Enterococcus faecium (DB14225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterococcus faecium probiotic (150 ml daily, 4.5 x 10^9 to 7.5 x 10^9 CFU E. faecium for 10 days)
Study: 11200372
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg orally q.i.d. for 10 days)
Study: 9357377
Drug: Albuterol by
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol by Ventolin metered-dose inhaler (2 puffs, 90 micrograms/puff)
Study: 9357377
Drug: Albuterol sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol sulfate powder (Rotacaps) by dry powder inhaler (2 inhalations, 100 micrograms/puff)
Study: 9357377
Drug: Lactose powder
Normalized name: Lactose Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose powder by dry powder inhaler (2 inhalations, 12.5 mg/inhalation)
Study: 2862995
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with low‐dose continuous prednisone (7.5 mg daily)
Study: 2862995
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy without prednisone
Study: 29126203
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg daily) with radiation therapy and concurrent/adjuvant temozolomide
Study: 29126203
Drug: Control (radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (radiation therapy with concurrent and adjuvant temozolomide without everolimus)
Study: 26714774
Drug: n‐3FA lovaza
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3FA lovaza 4 g
Study: 26714774
Drug: raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene 60 mg
Study: 26714774
Drug: raloxifene 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene 30 mg
Study: 26714774
Drug: lovaza 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovaza 4 g plus raloxifene 30 mg
Study: 24661672
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (RT)
Study: 15885299
Drug: Peto group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peto group sequential stopping method
Study: 14512132
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate monohydrate 50-microg nasal spray
Study: 14512132
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride 180-mg tablets
Study: 14512132
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical solution
Study: 8901655
Drug: High-dose Integrelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Integrelin (90 micrograms/kg bolus followed by 1.0 microgram.kg‐1.min‐1 continuous infusion)
Study: 8901655
Drug: Low-dose Integrelin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Integrelin (45 micrograms/kg bolus followed by 0.5 microgram.kg‐1.min‐1 continuous infusion)
Study: 1809429
Drug: p.r.n. intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.r.n. intravenous morphine
Study: 6882604
Drug: Atenolol (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (during treatment)
Study: 31444917
Drug: Poloxamer-based thermo-sensitive
Normalized name: Poloxamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer-based thermo-sensitive sol-gel instillation
Study: 24841163
Drug: Ciclesonide (CIC)
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide (CIC) 320 μg once daily
Study: 24841163
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 200 μg two inhalations twice daily
Study: 22007656
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb exercises followed by manual therapy (MT)
Study: 17312210
Drug: Sugammadex, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex, 4 mg/kg IV (n = 20)
Study: 17312210
Drug: Edrophonium, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium, 1 mg/kg IV and atropine, 10 microg/kg IV (n = 20)
Study: 15802292
Drug: N(G)-monomethyl-L-arginine (L-NMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (L-NMMA) infusion
Study: 9852985
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (Oka strain) at 3200 pfu/dose
Study: 9852985
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (Oka strain) at 8500 pfu/dose
Study: 9852985
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (Oka strain) at 41,650 pfu/dose